PDT Partners LLC Buys New Holdings in ANI Pharmaceuticals, Inc. $ANIP

Posted by George Bondi on Aug 27th, 2026

PDT Partners LLC bought a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The firm bought 45,442 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,762,000.

Other institutional investors have also recently bought and sold shares of the company. Maryland State Retirement & Pension System increased its holdings in ANI Pharmaceuticals by 5.4% in the 4th quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock valued at $206,000 after buying an additional 134 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of ANI Pharmaceuticals by 1.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock worth $736,000 after acquiring an additional 143 shares during the period. CANADA LIFE ASSURANCE Co boosted its position in shares of ANI Pharmaceuticals by 1.0% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after acquiring an additional 198 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its position in shares of ANI Pharmaceuticals by 5.1% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock valued at $323,000 after acquiring an additional 200 shares in the last quarter. Finally, Federation des caisses Desjardins du Quebec increased its stake in ANI Pharmaceuticals by 0.6% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 39,391 shares of the specialty pharmaceutical company’s stock valued at $3,110,000 after acquiring an additional 221 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Down 1.4%

Shares of NASDAQ:ANIP opened at $74.56 on Thursday. The company’s fifty day moving average is $79.93 and its 200-day moving average is $78.75. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. ANI Pharmaceuticals, Inc. has a 52 week low of $70.15 and a 52 week high of $99.50. The company has a market capitalization of $1.71 billion, a PE ratio of 16.07 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.04 by $0.17. The firm had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm’s quarterly revenue was up 25.8% on a year-over-year basis. During the same period last year, the firm posted $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Canaccord Genuity Group decreased their price objective on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Finally, Guggenheim cut their target price on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $105.83.

View Our Latest Report on ANIP

Insider Buying and Selling

In related news, CEO Nikhil Lalwani sold 5,400 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $74.30, for a total transaction of $401,220.00. Following the sale, the chief executive officer directly owned 344,489 shares in the company, valued at $25,595,532.70. This represents a 1.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $75.48, for a total value of $37,740.00. Following the sale, the vice president directly owned 74,424 shares of the company’s stock, valued at $5,617,523.52. This represents a 0.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 24,387 shares of company stock valued at $1,947,625 in the last ninety days. 8.10% of the stock is owned by corporate insiders.

About ANI Pharmaceuticals

(Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.